Related Experiment Video

Updated: Jan 29, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Aldose reductase inhibitors: 2013-present

Luca Quattrini1, Concettina La Motta1

  • 1a Dipartimento di Farmacia , Università di Pisa , Pisa , Italy.

Expert Opinion on Therapeutic Patents
|February 15, 2019
PubMed
Abstract

Insights

Aldose reductase (ALR2) inhibitors are crucial for treating diabetic complications and inflammatory diseases. Recent research highlights natural compounds and novel synthetic derivatives like ARDIs as promising therapeutic agents.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Aldose reductase (ALR2) is implicated in diabetic complications and inflammatory conditions.
  • ALR2's role in the polyol pathway under hyperglycemia makes it a significant drug target.
  • Inhibition of ALR2 is pursued for therapeutic interventions in both diabetic and inflammatory diseases.

Purpose of the Study:

  • To review patents and applications for aldose reductase inhibitors over the past five years.
  • To analyze natural, semi-synthetic, and synthetic ALR2 inhibitors from chemical and functional perspectives.
  • To identify emerging trends and promising candidates in ALR2 inhibitor development.

Main Methods:

  • Literature survey of patents and patent applications.
  • Analysis of chemical structures and functional properties of ALR2 inhibitors.
  • Review of preclinical data for efficacy and safety.

Main Results:

  • Numerous ALR2 inhibitors show preclinical promise for diabetic and inflammatory diseases.
  • Natural compounds and plant extracts are prevalent, indicating a trend towards phytopharmaceuticals.
  • Synthetic differential inhibitors (ARDIs) show potential to improve efficacy and reduce side effects compared to classical inhibitors.

Conclusions:

  • The field of aldose reductase inhibitors is active, with significant preclinical development.
  • Natural products remain a key focus, alongside innovative synthetic approaches like ARDIs.
  • Novel ALR2 inhibitors, particularly ARDIs, offer a promising strategy to overcome limitations of existing treatments.
Keywords:
Aldose reductasealdose reductase differential inhibitorsaldose reductase inhibitor patentsaldose reductase inhibitorsphytoparmaceuticalssemi-synthetic inhibitorssynthetic inhibitors

More Related Videos

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms03:29

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Published on: May 31, 2024

930
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
644
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
570